19
|
Periquet M, Lücking CB, Vaughan JR, Bonifati V, Dürr A, De Michele G, Horstink MW, Farrer M, Illarioshkin SN, Pollak P, Borg M, Brefel-Courbon C, Denefle P, Meco G, Gasser T, Breteler MMB, Wood NW, Agid Y, Brice A. Origin of the mutations in the parkin gene in Europe: exon rearrangements are independent recurrent events, whereas point mutations may result from Founder effects. Am J Hum Genet 2001; 68:617-26. [PMID: 11179010 PMCID: PMC1274475 DOI: 10.1086/318791] [Citation(s) in RCA: 79] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2000] [Accepted: 01/02/2001] [Indexed: 11/03/2022] Open
Abstract
A wide variety of mutations in the parkin gene, including exon deletions and duplications, as well as point mutations, result in autosomal recessive early-onset parkinsonism. Interestingly, several of these anomalies were found repeatedly in unrelated patients and may therefore result from recurrent, de novo mutational events or from founder effects. In the present study, haplotype analysis, using 10 microsatellite markers covering a 4.7-cM region known to contain the parkin gene, was performed in 48 families, mostly from European countries, with early-onset autosomal recessive parkinsonism. The patients carried 14 distinct mutations in the parkin gene, and each mutation was detected in more than one family. Our results support the hypothesis that exon rearrangements occurred independently, whereas some point mutations, found in families from different geographic origins, may have been transmitted by a common founder.
Collapse
Affiliation(s)
- Magali Periquet
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Christoph B. Lücking
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Jenny R. Vaughan
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Vincenzo Bonifati
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Alexandra Dürr
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Giuseppe De Michele
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Martin W. Horstink
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Matt Farrer
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Sergei N. Illarioshkin
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Pierre Pollak
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Michel Borg
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Christine Brefel-Courbon
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Patrice Denefle
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Giuseppe Meco
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Thomas Gasser
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Monique M. B. Breteler
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Nick W. Wood
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Yves Agid
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | - Alexis Brice
- INSERM U289, Consultation de Génétique Médicale, and Fédération de Neurologie, Hôpital de la Salpêtrière, Paris; Institute of Neurology, London; Dipartimento di Scienze Neurologiche, Università “La Sapienza,” Rome; Dipartimento di Scienze Neurologiche, Università Federico II, Naples; Academisch Ziekenhuis Nijmegen, Nijmegen, The Netherlands; Laboratory of Neurogenetics, Departments of Neuroscience and Neurology, Mayo Clinic, Jacksonville, Florida; Department of Neurogenetics, Institute of Neurology, Moscow; Clinique Neurologique, Centre Hospitalier Universitaire de Grenoble, Grenoble; Service de Neurologie, Hôpital Pasteur, Nice; INSERM U317, Service de Pharmacologie Clinique, Toulouse; Biotechnology Department, Aventis Pharma, Vitry sur Seine, France; Neurologische Klinik der Ludwig-Maximilians-Universität, Munich; and Department of Epidemiology and Biostatistics, Rotterdam
| | | | | |
Collapse
|